Bacteremia is typically treated with intravenous (IV) antibiotics for a duration determined by the nidus of infection. In some cases, such as pneumonia, there is sufficient evidence for guidelines to recommend oral (PO) antibiotics. 1 In other situations, clinicians must use judgment based on factors such as persistence of bacteremia, likely susceptibility of potential pathogens to appropriate antibiotics, predicted adequacy of drug absorption and penetration at the site of infection, host immune status, anticipated adherence, and reliability of follow-up.
Some evidence supports the use of PO fluoroquinolones for bacteremic urinary tract infections (UTIs). One study showed that patients treated with ciprofloxacin or levofloxacin, whether administered IV or PO, had negative cultures at the test of cure. 2 Another investigation of the treatment of pyelonephritis with ciprofloxacin demonstrated the effectiveness of PO therapy despite 42% of patients having positive blood cultures. 3 In addition, a study examining the cost savings of an IV-to-PO transition for bacteremia found that length of hospital stay (LOS) decreased by 6 days and hospital days on antibiotics decreased by 2 days in the IV-to-PO transition group. 4 When assessed, the common predictors for not deescalating were documented fluoroquinolone resistance, bacteria other than Escherichia coli, and discharge to a long-term care facility. 5 The purpose of the current study was to examine failure rates among patients receiving exclusively IV antibiotics (IV-only) compared with partial or complete treatment with PO (referred to as IV/PO) antibiotics for Enterobacteriaceae bacteremic UTIs.
Methods
Following approval by the institutional review board at the Medical University of South Carolina (MUSC), a retrospective cohort study of patients with Enterobacteriaceae bacteremic UTI was conducted. Patients ≥ 18 years old hospitalized between July 1, 2010, and June 30, 2015, were included. Enterobacteriaceae bacteremic UTI was defined as occurring in patients with positive urine and blood cultures, collected within a 24-hour period, with the same pathogen (i.e., Enterobacter spp., E. coli, Klebsiella spp., Proteus spp., Serratia marcescens, Citrobacter spp., Morganella morganii, or Providencia spp). Exclusion criteria were inability to receive PO therapy (e.g., pathogen not susceptible to any PO antibiotic; allergy to PO antibiotics to which organism was susceptible), ongoing receipt of total parenteral nutrition, and patients with long-term vascular access such as a port or tunneled central venous catheter. Eligible patients were identified, and baseline characteristics were extracted from an internal database. International Classifications of Disease (ICD) codes were used to calculate the Charlson Comorbidity Index (CCI). [6] [7] [8] The medical record (EPIC starting in July 2014 and McKesson-Horizon Meds Manager from July 2010 to July 2014) was also reviewed for relevant study data including antibiotics, pathogen susceptibilities, and information related to treatment course. The two treatment groups, IV-only and IV/PO, were compared for the composite primary outcome of documented failure of therapy, defined as escalation to IV from PO antibiotic, change in antibiotic due to worsening clinical status, or readmission for the same infection and pathogen (either UTI and/or bacteremia) within 30 days of discharge. At our institution, patients admitted with bacteremic UTI often are started on IV antibiotics initially and then transitioned to PO antibiotics on the day before discharge. Secondary outcomes of LOS and hospital days on antibiotics were also evaluated. Outcomes were assessed between groups using Fisher's exact test or Wilcoxon rank sum tests, as appropriate, due to the low failure rates and relatively small sample size. Continuous data are represented as median (interquartile range [IQR] ) in the results. In order to account for differences in severity of illness, generalized linear models were also used to compare group (IV-only vs IV/ PO) differences while accounting for CCI scores.
Results
Two hundred forty-one patients met the inclusion criteria. The median age of the patients was 64 (54-74) years, 46% were male, and patients were predominantly African American (53%) or white (46%; Table 1 ). CCI was 7 (4-10), and most patients had diabetes, often with comorbid renal disease. LOS was 5.2 (3.7-10.9) days, with 25.7% of patients being admitted directly to the ICU. ICU LOS was 93 (38-349) hours for the IV-only group and 65 (46-109) hours for the IV/PO group. Overall, 42 (39.6%) of the IVonly group were admitted to the ICU versus 37 (27.4%) of the IV/PO group (p=0.045).
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Bacteremia was identified within 72 hours of admission in 88.8% of patients. One hundred six (44%) patients were treated with IV-only and 135 patients (56%) were treated with IV/PO, five of whom received PO antibiotics only. Pathogens isolated from blood and urine cultures were predominately E. coli (56.8%) and K. pneumoniae (22.8%). E. coli was the pathogen in 50% (95% confidence interval [CI]: 40-60%) of the IV-only group and 62% (95% CI: 53-70%) of the IV/PO group (p=0.07). Polymicrobial infections (two or more pathogens) with the same Enterobacteriaceae isolates in blood and urine were found in 1% of patients. Multidrug-resistant (MDR) pathogens, which are defined as resistance to three or more antimicrobial classes, were found in 39% (95% CI: 29-49%) of the IV-only group and 23% (95% CI: 16-31%) of the IV/PO group (p=0.01). Discharge antibiotics were predominantly ciprofloxacin (65.3%), various b-lactam antibiotics (19%), and trimethoprim-sulfamethoxazole (TMP-SMX; 9.1%) if given PO (n=121) and ceftriaxone (73.9%), cefepime (5.8%), and ertapenem (5.8%) if given IV (n=69).
There was no significant difference in the primary outcome of documented treatment failure in the IV-only group (3.8% [95% CI: 1.0-9.4%] failure) compared with the IV/PO group (8.2%
[95% CI: 4.1-14.1%] failure; p=0.19). The IVonly group had 14.2% (95% CI: 8.1-22.3%) all--cause mortality during hospitalization versus 2.2% (95% CI: 0.5-6.4%) of the IV/PO group (p<0.001). Hospital days on antibiotics were fewer in the group treated with PO antibiotics (5 [3] [4] [5] [6] [7] days vs 6 [4-10] days; p<0.001). For the IV/PO group, median number of days of IV before switching to PO was 4 days (IQR 2-5; range 0-15). The IV/PO group includes five patients who exclusively received PO antibiotics and therefore had no days of IV antibiotics. LOS was less in the group treated with PO antibiotics (4.6 [3.1-7.8] days vs 7.1 [4.0-17.5] days; p<0.001). CCI was 8 (5-11) in the IV-only group versus 6 (4-9) in the IV/PO group (p=0.03). Because CCI differed between the IV-only group and the IV/PO group, all outcomes were reevaluated using CCI as a covariate in generalized linear models. Following adjustment for CCI, LOS remained significantly related to the group with IV-only having longer hospital stays (p=0.004). CCI was not found to be significantly related to LOS (p=0.2), death during hospitalization (p=0.4), or MDR pathogen (p=0.9). Also, the hospital days on antibiotics were still different between groups after adjustment for CCI (p<0.001). Neither CCI nor treatment group was related to failure in multivariate analysis. 
TRANSITION FROM IV TO PO ANTIMICROBIALS FOR BACTEREMIC UTI Rieger et al
Failures in the IV-only group (n=4) occurred in patients with E. cloacae, P. mirabilis, E. coli, and M. morganii infection. Three patients with IV-only failure were admitted to the ICU, and all three had MDR pathogens. Failures in the IV/ PO group (n=11) occurred in patients with E. coli (n=5), K. pneumoniae (n=3), S. marcescens (n=2), and P. mirabilis (n=1) infection. MDR pathogens were present in 4 of 11 patients in the IV/PO failure subgroup. Overall, reasons for failure were readmission within 30 days with same infections (five total = one IV-only and four 4 IV/PO), escalation from PO to IV antibiotic (five total = five IV/PO; note that this cannot be detected in the IV-only group), and change in antibiotics due to declining clinical status (six total = three IV/PO and three IVonly).
For 5 of the 11 treatment failures in the IV/ PO group, the criterion for failure was escalation from PO to IV therapy, an outcome that cannot, by definition, be detected in the IV-only group and may be secondary to clinical reasons other than treatment failure, which may bias to detect more failure in the IV/PO group. The rationale for antibiotic changes was not always clearly documented, so if the patient could have been worsening clinically, this was assumed to be a failure. Adverse events associated with IV therapy, such as extravasation or catheter-associated infections or complications, were not addressed in the study. Patient adherence to any therapy after discharge was not assessed. However, four of the six IV/PO patients prescribed a PO fluoroquinolone at discharge who experienced treatment failure were also discharged on a scheduled polyvalent cation, which may have contributed to treatment failure. None of the five patients receiving only PO antibiotics (included in the IV/PO group for analysis) experienced treatment failure, and two of the five patients treated with only PO antibiotics had MDR pathogens.
Discussion
This study included patients treated with PO antibiotics for bacteremic UTI and involved a variety of pathogens and antibiotic regimens. Overall, there was no difference in treatment failure between the IV-only group and the IV/PO group. However, shorter LOS and fewer hospital days on antibiotics were observed for the IV/PO group versus the IV-only group. While this study was not designed to examine whether patients remained hospitalized to complete a course of IV antibiotics, it might be inferred from the lower frequency of discharge on IV antibiotics. Typical practice at our institution is to initiate patients admitted for bacteremic UTI with IV antibiotics and transition to PO the day before discharge, which is reflected in the median 4 days of IV before transitioning to PO antibiotics for the IV/ PO group. Facilitating discharge by using PO antibiotics may potentially reduce hospitalization costs or improve patient satisfaction scores. LOS was calculated from admission to discharge and not from time of documented infection to discharge. However, because 88.8% of patients were found to be bacteremic within 72 hours of admission, LOS is a decent surrogate marker for the impact of the infection on LOS. Including critically ill patients with longer ICU admissions in the study limits the generalizability of LOS as an outcome given the patients' complex illness and multifactorial reason for longer LOS. In addition, in this study, 46% of the population was male and urologic abnormalities were not quantified, which could have led to more failure from complicated UTI.
It appears that the IV-only group included more severely ill patients in aspects beyond the CCI (Table 1) . These patients had a higher incidence of infection with MDR organisms and longer ICU LOS and were more often admitted to the ICU. Nonetheless, accounting for CCI did not affect the results for primary or secondary outcomes. However, CCI is calculated from ICD-9 and ICD-10 codes and, therefore, there is potential for coding errors.
One factor unique to this institution that might have influenced prescribing is a formulary restriction of ciprofloxacin to a documented susceptible pathogen and nonformulary status of levofloxacin. Historically, relatively low susceptibilities of typical target pathogens, namely P. aeruginosa and E. coli, led to this restriction. Because these drugs exhibit many desirable characteristics including high concentrations in the genitourinary system, similar concentrations with PO and IV dosing, and low cost, higher use may have yielded different results, possibly improving the favorability of IV/PO treatment.
In light of these limitations, similar results in a larger study population to corroborate the findings of this study and elucidate risk factors for failure would further enhance clinical decision-making. A publication on the effectiveness of PO antibiotics in the treatment of gram-negative bloodstream infections included 70.2% 1482 PHARMACOTHERAPY Volume 37, Number 11, 2017 patients with bacteremia from a urinary source and found that antibiotics with high bioavailability had a lower rate of failure than antibiotics of moderate or low bioavailability. 9 However, the evidence that PO therapy can be used successfully to complete the treatment course for Enterobacteriaceae bacteremic UTI, coupled with the potential for reducing costs with shorter LOSs and fewer hospital days on antibiotics, provides a foundation for use of PO antibiotics in this situation.
Conclusion
IV/PO treatment was associated with a shorter LOS and fewer hospital antibiotic days compared with IV-only therapy. No statistically significant differences in treatment failures were observed between groups. Transitioning from IV to PO antibiotic therapy is a viable treatment option to consider for patients with bacteremic Enterobacteriaceae UTI.
